LOGGIC-Core

Low grade glioma (LGG)

Registry for molecular and clinical data for patients with low grade glioma (LGG)

Low grade glioma (LGG) is a heterogeneous group of different WHO grade I and II brain tumours associated with a 10-year overall survival of 94% and a 10-year
progression-free survival rate of 44% with standard of care (SOC) chemotherapy. The majority of patients with an LGG of the posterior fossa will remain under medical observation following initial diagnosis and primary surgery (i.e. primary watch-and-wait). However, more than three patients overall will need drug treatment for non-resectable, clinically symptomatic and/or radiologically progressivedisease, and many will suffer from multiple relapses and treatments.

The overall aim of the LOGGIC Core BioClinical Data Bank (LOGGIC Core) is to set up a molecular and clinical data bank for paediatric low grade gliomas (LGG). The data will be used to enhance the understanding of tumourbiology of the disease but also to correlate molecular subgroups of LGG with clinical outcome.

Objectives

• To collect molecular tumour characteristics of LGG patients at diagnosis and optionally at relapse/progression for exploratory analysis of biomarker and clinical outcome and to provide these data to other studies of the LOGGIC series.
• To collect baseline histological and clinical follow-up data.
• To explore improvement of diagnostic accuracy for all LGG patients included in LOGGIC Core by adding molecular information to reference histological/radiological evaluation, and to investigate the existence of possible new, molecularly-defined LGG subtypes.
• To describe clinically relevant target patterns and frequencies in paediatric low grade gliomas, including identification of novel targets.
• To identify biomarkers for treatment response and natural course of disease by linking histopathological and molecular data with radiological and clinical follow-up data.
• To explore feasibility of liquid biopsy analysis on different sources including blood and intraoperative CSF as potential biomarker for diagnosis and response to treatment as well as other exploratory biological studies.
• To set up an ex-vivo drug testing and model development pipeline on viable tumour tissue.

• age < 21 years.
• At primary diagnosis: Histologically verified low-grade glioma / glioneuronal tumour WHO grade I or II.
• Fresh frozen and paraffin tumour material together with blood available for molecular diagnostics. Exceptions (i.e. MRI based diagnosis) can be accepted only where a biopsy would pose an unacceptable risk to damage of eloquent brain structures.
• At relapse/progression: Fresh frozen and paraffin tumour material together with blood available wfor molecular diagnostics from primary diagnosis and/or current episode (preferably) of relapse/progression. No exceptions for the submission of fresh frozen and paraffin tumour material with blood
• Before patient registration, written informed consent, including data and tumour material transfer, must be given according to ICH/GCP, and national/local regulations.
• Residency in one of the participating countries of LOGGIC Core.

• Praticipation in HIT-LGG 2004 Registry